Tango Therapeutics Files 8-K on Shareholder Votes and Bylaws
Ticker: TNGX · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1819133
Sentiment: neutral
Topics: corporate-governance, filing, financials
TL;DR
Tango Therapeutics filed an 8-K detailing shareholder votes and corporate changes, with financials included.
AI Summary
Tango Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting on matters submitted to a vote of security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, with the earliest event reported being June 5, 2025. Tango Therapeutics, incorporated in Delaware, is in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides updates on corporate governance and financial reporting for Tango Therapeutics, which is crucial for investors to understand the company's operational and legal standing.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing procedural matters and financial statements, not indicating any immediate operational or financial distress.
Key Numbers
- 001-39485 — SEC File Number (Identifies the specific filing for Tango Therapeutics)
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Registrant
- BCTG Acquisition Corp. (company) — Former Company Name
- June 5, 2025 (date) — Earliest event reported
- June 6, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-39485 (filing_number) — SEC File Number
- 201 Brookline Avenue Suite 901 Boston, MA 02215 (address) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not elaborated upon in the provided text.
What were the key amendments to Tango Therapeutics' articles of incorporation or bylaws?
The filing states there were amendments to the articles of incorporation or bylaws, but the specific nature of these amendments is not detailed in the provided excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 5, 2025.
What is Tango Therapeutics' principal executive office address?
Tango Therapeutics' principal executive office is located at 201 Brookline Avenue, Suite 901, Boston, MA 02215.
What was Tango Therapeutics' former company name?
Tango Therapeutics, Inc. was formerly known as BCTG Acquisition Corp.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding Tango Therapeutics, Inc. (TNGX).